[Effects of antiarrhythmic drugs on canine ventricular arrhythmia models]. 1989

K Hashimoto
Department of Pharmacology, Yamanashi Medical College, Japan.

In order to compare and clarify the effects of various antiarrhythmic drugs, we examined drug effects on several canine arrhythmia models, simultaneously determining the minimum effective plasma concentrations. We used 1) two-stage coronary ligation arrhythmia, 2) digitalis arrhythmia, and 3) halothane-adrenaline arrhythmia. The following are, a summary of our results: Antiarrhythmic drugs of class 1 all suppressed digitalis arrhythmia, and except for lidocaine, also suppressed coronary ligation arrhythmia. Class 2 antiarrhythmic drugs, beta blockers, and class 4 antiarrhythmic drugs, Ca channel blockers, had common features of effectiveness, where they suppressed adrenaline arrhythmia in relatively low concentrations. Some differences among the antiarrhythmic effects of class 1 drugs could not be explained by their subclassification based either on action potential duration or kinetic properties of dissociation or association with Na channels. A new arrhythmia model for triggered activity in in vivo canine heart was developed, but drug effects on it does not seem to be very different from the effects on the other three arrhythmia models.

UI MeSH Term Description Entries
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000889 Anti-Arrhythmia Agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic
D001145 Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction. Arrhythmia,Arrythmia,Cardiac Arrhythmia,Cardiac Arrhythmias,Cardiac Dysrhythmia,Arrhythmia, Cardiac,Dysrhythmia, Cardiac

Related Publications

K Hashimoto
January 1994, General pharmacology,
K Hashimoto
March 2015, Asian Pacific journal of tropical medicine,
K Hashimoto
March 2000, Pacing and clinical electrophysiology : PACE,
K Hashimoto
July 1984, Journal of clinical pharmacology,
K Hashimoto
March 1988, Journal of cardiovascular pharmacology,
Copied contents to your clipboard!